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INTRODUCTION
Structural abnormalities of the coronary arteries and
their consequences are known to be responsible for 80%
of fatal arrhythmias (1,2). Huikuri et al. have shown that
patients with previous myocardial infarction, low
ejection fraction and ventricular tachycardia are at
much higher risk of sudden cardiac death (SCD)
compared to the general population (3). Several trials
have investigated primary and secondary prevention of
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ABSTRACT: Aims: The primary aim of this retrospective study was to determine the proportion
of patients with myocardial infarction (MI) who fulfil the criteria of the Multicenter Automatic
Defibrillator Implantation Trial (MADIT) II and the implications of MADIT II criteria in practice.
Methods: We performed a retrospective analysis of three hundred and ninety four admissions to
the Coronary Care Unit (CCU) of the Royal Infirmary of Edinburgh. We selected those with
myocardial infarction (MI) and attempted to retrieve electronic copies of their echocardiogram
reports. When available, these were used to assess requirement for primary-prevention
Implantable Cardioverter Defibrillator (ICD) therapy based on reported left ventricular function.
Results: One hundred and ninety patients were admitted to the CCU with a diagnosis of MI. Of
these, 100 patients (51.5%) had an echocardiogram. Requirement for ICD therapy was unlikely in
87 (87%), probable in 6 (6%) and necessary in 7 (7%). Since a significant number of patients in
the probable category were also likely to meet MADIT II criteria, we concluded that the proportion
of patients requiring primary-prevention ICD therapy would be no less than 7% and more likely
to be 13%. Conclusion: In the context of a busy teaching hospital, a figure of 13% for the
requirement of ICD therapy in MI patients represents annual implantation activity of at least 100
per million. This is likely to have very significant resource implications.
SCD using anti-arrhythmic drugs or implantable
cardioverter-defibrillators (ICDs). Primary-prevention
trials based on anti-arrhythmic drugs, other than beta-
blockers, have demonstrated either no survival benefit
(4,5) or, at worst, adverse outcomes (6.7). In contrast,
recent evidence from the Multicenter Automatic
Defibrillator Trial II (MADIT II) suggests that
prophylactic ICD therapy produces a significant
survival benefit in patients with prior myocardial
infarction and advanced left ventricular dysfunction (8).
This finding is consistent with earlier trials, such as
MADIT, the Multicenter Unsustained Tachycardia Trial
(MUSTT) and the Antiarrhythmics Versus Implantable
Defibrillators study (AVID), which showed a
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formally assessed. Secondly, it is the policy of our CCU
to refer for departmental echocardiography patients
who do not have clinical evidence of left ventricular
impairment in the immediate post-MI period. This
implies that amongst patients who did not have a
departmental echocardiogram, the proportion requiring
ICD therapy would be greater than amongst those who
did have an echocardiogram. The sum of the proportion
of patients classified as necessary and probable
candidates was therefore deemed a better estimate of
the proportion of patients requiring ICD therapy (p ICD).
Using mortality data from MADIT II and our
findings, we constructed a mathematical model to
forecast the number of patients requiring follow-up
after ICD therapy for primary-prevention. This model,
based on a geometric series, assumes constant annual
ICD implantation activity and mortality such that the
total burden of ICD patients at the end of each year can
be expressed as follows:
(y= number of years, pICD= proportion requiring ICD
therapy, A CCU = total MI admissions to CCU /  year, M=
population mortality)
Our projections were limited to 5 years because of the
potential impact of other variables, such as lifetime of
the ICD device, which necessitate consideration in a
long-term evaluation. 
RESULTS
Table I summarises our findings. Between 1st
October 2001 and 31st March 2002, a total of 394
patients were admitted to the CCU of our teaching
hospital. Of these, 190 (48.2%) had a clear diagnosis of
MI. 131 (68.9%) were males and 59 (31.1%) were
females. The age range was 30 to 95 years (Mean 65.7
years).  We retrieved a total of 100 echocardiogram
(Echo) reports, representing 51.5% of the total number.
Using our classification, requirement for ICD therapy
was unlikely in 87 patients (87%), probable in 6 (6%)
and necessary in 7 (7%). By extrapolation, these results
suggest that, over a 12-month period, requirement for
ICD therapy will be probable in 23 and necessary in 27
(figure 1). We concluded that our overall annual
estimate for new ICD implants would be at least 27 (7%
of CCU MI admissions being necessary candidates) but
more likely to be closer to 50 (13% of CCU MI
admissions). This represents a potential increase of
125% in ICD implantation activity in our hospital (table
I).
significant benefit of ICD therapy over anti-arrhythmic
medication (9,10). Compared to the design of MADIT
and MUSTT, where patients underwent invasive
electrophysiological testing to determine risk of
arrhythmia, MADIT II criteria were simplified on the
grounds that myocardium damaged by infarction and
rendered severely dysfunctional is a trigger for fatal
arrhythmias by the process of macro re-entry (8).
Therefore, the findings of MADIT II apply to a large
proportion of patients with previous MI and severely
impaired left ventricular function.
A major obstacle to the application of findings from
randomised trials, such as MADIT II, is the absence of
data on the proportion of patients who fulfil inclusion
criteria.  The purpose of our audit was to address this
problem and to evaluate, both quantitatively and
qualitatively, the potential implications of MADIT II
criteria in the context of a busy teaching hospital.
METHODS
Using the Ward Register, we identified all admissions
to the Coronary Care Unit (CCU) at the Royal Infirmary
of Edinburgh over a period of 6 months from 1st
October 2001 to 31st March 2002. Of these, we selected
those with a diagnosis of myocardial infarction (MI)
based on ST segment elevation and a rise in cardiac
enzymes. We then attempted to retrieve electronic
copies of echocardiogram reports for each patient. A
retrieval rate of 100% was not expected on account of
the absence of electronic reports for patients having had
portable echocardiography performed in the CCU. In
cases where reports were available, only the latest was
considered. Patients were then classified according to
their reported left ventricular function. 
MADIT II findings apply to patients with prior MI
and a left ventricular ejection fraction (LVEF) less than
30% (8). While the design of this simple retrospective
study did not permit us to quantify LVEF, we reasoned
that primary-prevention ICD therapy in our study
population could be classified as necessary, probable or
unlikely on the basis of the echocardiogram report
which provided a subjective assessment of left
ventricular function. Patients with reported normal,
mild or mild / moderate impairment were considered
unlikely to require ICD-therapy, those with moderate or
moderate/severe impairment were probable candidates,
and those with severe impairment were necessary
candidates.
In determining the proportion of MI patients who
would require primary-prevention ICD therapy, two
additional factors were considered. First, amongst
patients who were probable candidates for ICD therapy,
it was likely that a significant proportion would meet
MADIT II criteria if left ventricular function were16 McGill Journal of Medicine 2006
Using MADIT II findings, we calculated an annual
mortality rate of 9.1% for patients having received ICD
therapy for primary prevention (8). We then applied our
model to forecast the number of patients requiring
follow-up for primary prevention ICD therapy in our
hospital:
(y= number of years, pICD= proportion requiring ICD
therapy = 0.13, ACCU = total MI admissions to CCU /
year = 380, M= population mortality = 0.091)
Our results, illustrated in figure 2, show that the
number of primary-prevention ICD patients requiring
follow-up is likely to reach 100 within 2 years and then
double within 5 years of implementing MADIT II
criteria.
DISCUSSION
It is estimated that secondary-prevention ICD
implantation averages 17 per million in the United
Kingdom.  This figure has been reported as being less
than half of that for Western Europe and less than 10%
of that in the USA 12. Prior to MADIT II, the use of
ICD therapy for primary prevention was controversial.
Studies such as the Canadian Implantable Defibrillator
Study (CIDS) and Coronary Artery Bypass Graft
(CABG) Patch trial found no statistically significant
reduction in mortality from the use of ICD therapy for
secondary prevention and primary prevention,
respectively (13,14). The 2002 guidelines from the
American College of Cardiology and the American
Heart Association (ACC/AHA) include the use of ICD
therapy for primary prevention in patients with left
ventricular ejection fraction of less than or equal to 30%
at least 1 month post myocardial infarction and 3
months post coronary artery revascularization surgery
(15). This is currently a class IIa recommendation based
on increasing evidence in favour of ICD therapy in this
setting.  Implementation of this recommendation in
conjunction with MADIT II criteria is likely to have
important implications for resource allocation and
Table I – Summary of findings for each calendar month (October 2001 to March 2002)
Oct Nov Dec Jan Feb Mar Overall
Total Admissions 68 53 65 78 57 73 394
MI Adminssions (%) 34 (50.0) 15 (28.3) 29 (44.6) 45 (57.7) 34 (59.6) 33 (45.2) 190 (48.2)
Mean age / years 66.6 66.7 65.0 67.6 65.7 62.6 65.7
No. of Males with MI (%) 21 (61.8) 13 (86.7) 21 (72.4) 30 (66.7) 22 (64.7) 24 (72.7) 131 (68.9)
No. of Females with MI(%) 13 (38.2) 2 (13.3) 8 (27.6) 15 (33.3) 12 (35.3) 9 (27.3) 59 (31.1)
Retrieved Echos (%) 25 (73.5) 9 (60.0) 11 (37.9) 23 (51.1) 16 (47.1) 16 (48.5) 100 (51.5)
ICD Requirement:
Unlikely 2 18 1 01 91 51 4 8 7
Probable 210201 6
Required 201211 7
2º prevention ICDs 833132 2 0
2º prevention ICDs = Seconday prevention ICD implants
Figure 2 - Cumulative burden of primary-prevention ICD patients
over 5 years.Implantable Cardioverter-Defibrillator Therapy  17 Vol. 9 No. 1
policy making in the National Health Service (NHS).
This discussion focuses on the ramifications in the
context of a busy teaching hospital and specialist
regional implanting centre.
In the MADIT II trial, patients who were eligible for
inclusion had undergone objective assessment of LVEF
by angiography, radionuclide scanning or
echocardiography (12). In our audit study, only 51.5%
of patients were referred for echocardiography. There
was also no formal objective assessment of LVEF.
While these constitute intrinsic methodological
limitations, they are also a reflection of current practice.
Evidence-based selection and exclusion of patients for
primary-prevention ICD therapy is likely to involve a
much greater proportion of CCU patients undergoing
formal assessment of LVEF. Since echocardiography is
readily available and relatively cheap, expansion of the
service may be warranted in centres implementing
MADIT II findings.
As suggested by our study, about 13% of patients
admitted to CCU with MI require primary-prevention
ICD therapy. On an annual basis, the estimated 50 new
cases for a population of 500 000 in Edinburgh
(Scotland) are likely to increase ICD implantation
activity by at least 125%. Providing for a surge in
demand of this magnitude will have implications for
theatre time, staffing levels and the provision of extra
funds for hardware. Whereas implantation activity is
unlikely to vary significantly in the short term, the
cumulative burden of primary-prevention ICD patients
requiring follow-up is likely to increase substantially
(figure 2). According to guidelines from the British
Pacing and Electrophysiology Group (BPEG), every
increment of 100 patients justifies an additional follow-
up clinic run by 2 technicians and 1 physician (16).
Based on our model, by the end of year 5, 2 follow-up
clinics would be running at capacity. 
Our evaluation of the implications of MADIT II
criteria has been limited to a 5-year period on account
of the potential influence, in the long-term, of several
factors. As implantation activity increases, the cost of
ICD devices is expected to fall as a result of economies
of scale. Improvements in technology are likely to
improve the lifetime of the ICD device, thereby
reducing the requirement for replacement. As primary-
prevention ICD therapy gains acceptance, more District
General Hospitals may be involved in ICD implantation
and follow-up. This can reduce the burden on specialist
centres but also involves more emphasis on, and
investment in, the training of cardiologists with an
interest in pacemakers and ICDs.  Newer approaches
such as ablative therapy may also influence the use of
ICD therapy. Although no trials have been carried out,
there have been reports of recurrent monomorphic VT
following MI being treated successfully with single
catheter ablation and concomitant administration of
anti-arrhythmic drugs (17).
In conclusion, our retrospective study shows that at
least 13% of MI admissions to CCU are eligible for
primary-prevention ICD therapy. In the context of a
busy teaching hospital, annual implantation activity,
using MADIT II criteria, can be expected to reach as
much as 100 per million of population. As suggested by
our model, the cumulative number of patients having
received primary prevention ICD therapy is likely to
have major implications for follow-up clinics. To our
knowledge, this is the first study investigating the
implications of MADIT II criteria. While this study
provides useful preliminary information, further studies
are needed for more precise evaluation of short and
long-term cost implications of primary-pevention ICD
therapy.
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